OncoMatch/Clinical Trials/NCT05415709
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Is NCT05415709 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Carboplatin and Cisplatin for fallopian tube endometrioid adenocarcinoma.
Treatment: Carboplatin · Cisplatin · Hyperthermic Intraperitoneal Chemotherapy · Paclitaxel — This phase I trial studies the side effects of hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery in treating patients with stage III or IV ovarian, fallopian tube or peritoneal cancer receiving chemotherapy before surgery. Hyperthermic intraepithelial chemotherapy involves the infusion of heated cytotoxic chemotherapy that circulates into the abdominal cavity at the time of surgery. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery may kill more tumor cells compared to usual care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IIIA, IIIA1, IIIA2, IIIB, IIIC, IV, IVA, IVB (AJCC v8)
stage III or IV epithelial (serous, mucinous, or endometrioid) ovarian, fallopian tube or peritoneal cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin, paclitaxel) — neoadjuvant
Completion of three cycles of neoadjuvant chemotherapy (NACT) with standard therapy (carboplatin [AUC 5-6] D1 + paclitaxel [175 mg/m^2] D1 every 3 weeks)
Lab requirements
Blood counts
White blood cell count > 3.5 x 10^9 cells/L; Absolute neutrophil count > 1.5 kg/ul; Platelets > 100,000/ul
Kidney function
Serum creatinine < 1.4 mg/dL; Creatinine clearance > 60 ml/min (Cockcroft-Gault formula)
Liver function
Total bilirubin within 1.5 x normal institutional limits; AST and ALT <= 2.5 x institutional upper limit of normal
Serum creatinine < 1.4 mg/dL; Creatinine clearance > 60 ml/min (Cockcroft-Gault formula); White blood cell count > 3.5 x 10^9 cells/L; Absolute neutrophil count > 1.5 kg/ul; Platelets > 100,000/ul; Total bilirubin within 1.5 x normal institutional limits; AST and ALT <= 2.5 x institutional upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify